How effective is Spravato

How Effective Is Spravato? Research Explained | MedHaus

How Effective Is SPRAVATO®? Research Explained 

When you’ve tried antidepressants and still don’t feel like yourself, it can be discouraging. You may wonder whether another treatment could make a difference.

SPRAVATO® is an option for some adults with treatment-resistant depression. Research has explored how it can reduce symptoms, how quickly improvement may begin, and whether continued treatment helps people stay well. Here’s what those findings mean in everyday language.

What Is SPRAVATO?

SPRAVATO is a prescription nasal spray containing esketamine. 

Treatment-resistant depression generally means that depression has not improved enough after at least two antidepressant treatments taken at an adequate dose and for an adequate length of time. Having treatment-resistant depression does not mean you have run out of options.

SPRAVATO acts on NMDA receptors, which are involved in the brain’s glutamate signaling system. This differs from many traditional antidepressants. Glutamate is a chemical messenger that helps brain cells communicate and plays a role in learning, memory, and the brain’s ability to adapt.

Many traditional antidepressants, such as SSRIs and SNRIs, primarily affect serotonin or norepinephrine. SPRAVATO acts on a different signaling pathway by blocking NMDA receptors. However, the exact way this leads to improvement in depression is not fully understood.

For adults with treatment-resistant depression, SPRAVATO offers another treatment option when previous antidepressants have not provided enough relief. A different approach does not guarantee a response, but it means that unsuccessful treatment in the past does not rule out improvement with another option.

What Have SPRAVATO Research Studies Found?

TRANSFORM-2: Greater Improvement After Four Weeks

The TRANSFORM-2 study compared two groups of adults with treatment-resistant depression. One received SPRAVATO plus a newly started oral antidepressant. The other received a placebo nasal spray plus a newly started oral antidepressant.

Both groups improved. However, after four weeks, the SPRAVATO group had a greater average reduction in depression symptoms.

Researchers measured symptoms using a standardized depression rating scale. The SPRAVATO group had an adjusted average reduction of approximately 19.8 points, compared with 15.8 points in the comparison group. The additional 4-point reduction with SPRAVATO was statistically significant.

The findings support SPRAVATO as an additional treatment option, while recognizing that individual results vary.

SUSTAIN-1: Helping Prevent Symptoms From Returning

Feeling better is an important step. Maintaining that improvement matters, too.

The SUSTAIN-1 study looked at people who had already improved with SPRAVATO and an oral antidepressant. Researchers compared continuing SPRAVATO with switching to a placebo nasal spray. Everyone continued their oral antidepressant.

Among patients who had reached stable remission—meaning their depression symptoms were minimal—approximately:

  • 27% experienced a relapse while continuing SPRAVATO.

  • 45% experienced a relapse after switching to placebo nasal spray.

These percentages reflect what happened during the study’s maintenance period, rather than a fixed annual risk. Because participants had already benefited from treatment, the findings are most relevant to patients who improve with SPRAVATO and are considering ongoing care.

What Do These Results Mean for You?

The research offers reasons for hope, especially if you have tried several antidepressants without enough relief. However, study results describe how groups of people responded; they cannot predict exactly how SPRAVATO will work for you. 

Your clinician will review more than your diagnosis. They will consider which treatments you have tried, how long you took them, whether they helped, and any side effects you experienced. Your medical history, current medications, and other mental health conditions also help determine whether SPRAVATO is an appropriate option.

If you begin treatment, your clinician will monitor your symptoms, side effects, and daily functioning over time. Together, you can evaluate whether the benefits justify continuing and whether your broader treatment plan needs adjustment.

Not responding to previous antidepressants does not mean you have exhausted your options. SPRAVATO may offer another path to consider through an individualized discussion with your clinician.

Explore SPRAVATO Treatment at MedHaus

You deserve care that takes your experiences seriously. Understanding the research can help you feel more informed and prepared to discuss your options.

Learn more about SPRAVATO at MedHaus in Oakland, NJ.

Take the next step: Schedule a consultation at MedHaus.

Your Next Chapter Starts Here.

Take the first step toward feeling better with personalized, physician-led care designed around you.

Scroll to Top